Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
14.49
+0.24 (1.68%)
At close: Jul 16, 2025, 4:00 PM
14.51
+0.02 (0.14%)
After-hours: Jul 16, 2025, 7:30 PM EDT
Keros Therapeutics Revenue
Keros Therapeutics had revenue of $211.25M in the quarter ending March 31, 2025, with 254,413.25% growth. This brings the company's revenue in the last twelve months to $214.71M, up 91,657.69% year-over-year. In the year 2024, Keros Therapeutics had annual revenue of $3.55M with 2,250.99% growth.
Revenue (ttm)
$214.71M
Revenue Growth
+91,657.69%
P/S Ratio
2.61
Revenue / Employee
$1,270,491
Employees
169
Market Cap
588.52M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
KROS News
- 5 weeks ago - ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal - PRNewsWire
- 5 weeks ago - Keros Announces Return of $375 Million in Excess Capital to Stockholders - GlobeNewsWire
- 5 weeks ago - Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring - GlobeNewsWire
- 7 weeks ago - Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees - GlobeNewsWire
- 2 months ago - ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth - PRNewsWire
- 2 months ago - ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth - PRNewsWire
- 2 months ago - Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference - GlobeNewsWire